UPDATE: Morgan Stanley Cuts PT to $27 on Sagent Pharmaceuticals; Progress Amid Soft Q1

Morgan Stanley lowers its price from $28 to $27 on Overweight-rated Sagent Pharmaceuticals SGNT following Q1 results coming in below expectations. Morgan Stanley notes, "1Q12 revenue was below expectations, but positive pipeline and contracting updates support our long-term thesis of a broadening and profitable base driving revenue growth and margin leverage in an injectables market with attractive fundamentals." SGNT closed at $16.88 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetReiterationPre-Market OutlookAnalyst RatingsMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!